REVIEW

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms

Benjamin Crooks MA MBBS1,2, Tom Barnes MBBS BS3, Jimmy K Limdi FRCP FACG2,3,4
1Division of Diabetes, Endocrinology and Gastroenterology, University of Manchester, Manchester M13 9PL, UK; 2Section of IBD – Division of Gastroenterology, The Pennine Acute Hospitals NHS Trust, Manchester, UK; 3Manchester Academic Health Science Centre, University of Manchester, Manchester, UK; 4Manchester Metropolitan University, Manchester, UK

Abstract

Inflammatory bowel diseases, comprising Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, relapsing and remitting immune-mediated inflammatory diseases affecting the gastrointestinal tract. Vedolizumab is the first licensed drug in a group of ‘gut-selective’ biological agents used to treat inflammatory bowel diseases. The GEMINI registrational trials established the efficacy of vedolizumab for the induction and maintenance of remission in both CD and UC, with the most favourable results in tumour necrosis factor (TNF)-antagonist-naïve patients. In recent years, a wealth of ‘real-world’ data has emerged supporting positive clinical, endoscopic and histological outcomes in patients treated with vedolizumab (VDZ) as well as reassuring safety data. More recently, the results of the first head-to-head trials of VDZ and TNF antagonists have been reported, as well as the results of a number of studies exploring the role of therapeutic drug monitoring with VDZ. This review brings together data reported on VDZ to date, including from the GEMINI trials, real-world data and emerging studies regarding therapeutic drug monitoring and immunogenicity. The safety profile of VDZ is also reviewed. Evolving treatment paradigms are explored, including data regarding the role of VDZ in perianal CD, post-operative complications and recurrence, extraintestinal manifestations and pregnancy.

Keywords: Crohn’s disease, inflammatory bowel diseases, mucosal healing, safety, therapeutic drug monitoring, ulcerative colitis, vedolizumab.

Citation
Crooks B, Barnes T, Limdi JK. Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. Drugs in Context 2020; 9: 2019-10-2. DOI: 10.7573/dic.2019-10-2

Introduction

Inflammatory bowel diseases (IBDs), comprising Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, relapsing and remitting immune-mediated inflammatory diseases affecting the gastrointestinal tract.1,2 Conventional management has included use of broad-spectrum anti-inflammatory drugs such as aminosalicylates and corticosteroids or immunosuppressants such as thiopurines or methotrexate, often in a step-up manner, aiming to relieve symptoms and to an extent prevent long-term complications.3 The advent of anti-tumour necrosis factor (anti-TNF) therapy, showing efficacy in the induction and maintenance of remission, corticosteroid-sparing effects, mucosal healing and reduced rates of hospitalisation and surgery, has redefined meaningful disease control, providing much-needed impetus to the development of other biological therapies.3,4 Anti-TNF therapies are not universally effective, with up to 30% of patients demonstrating primary non-responsiveness and with 50% of patients showing secondary loss of response due to intolerance, immunogenicity or mechanistic failure.3,5 Furthermore, there is a risk of infectious complications attributable to non-specific TNF-mediated inhibition.4,7

Meanwhile, evolution of our understanding of T-lymphocyte biology orchestrating gut inflammation has led to the development of several agents directed against trafficking of effector T lymphocytes towards the gut mucosa.8 The premise for this development was the recognition that tissue injury in CD and UC occurs in areas where activated lymphocytes produce an array of inflammatory mediators. These cells are recruited from the bloodstream as a result of increased expression of adhesion molecules on the intestinal vascular endothelium and integrins on lymphocytes and excessive production of chemokines within the inflammatory microenvironment.8 Inhibition of leukocyte recruitment to the gut mucosa during the inflammatory process is a novel therapeutic target. Vedolizumab (VDZ) is the first and currently...
only licensed drug in this group of ‘gut-selective’ biological agents.9-12 The aim of this review is to summarise the current literature regarding the mechanism of action of VDZ, data from registrational trials on safety and efficacy, including open-label extension (OLE), observational and emerging real-world evidence on its effectiveness in the treatment of IBD, and evolving paradigms with VDZ. A thorough literature search was conducted using PubMed to identify all relevant articles published until August 2019.

Mechanism of action

As leukocytes travel through the bloodstream, a highly coordinated sequential adhesion pathway is activated, involving tethering, rolling, activation, adhesion and migration through the vascular wall. Infiltrating leukocytes secrete pro-inflammatory cytokines, leading to endothelial cell activation and up-regulation of adhesion molecules with enhancement of inflammatory cell recruitment.13 Adhesion molecules belong to the integrin family (leukocyte cell-surface adhesion molecules), which allow them to stop rolling and start migration through the vascular wall. Integrins involved in T-cell migration are leukocyte function-associated antigen 1 (LFA-1 or α2β2) and the two α4-integrins (α4β1 and α4β7).13,14 The subunit α is connected to specificity, and subunit β relates to signalling. Integrins bind to specific ligands on the endothelium called addressins or adhesion molecules. The integrin α4β7 is expressed on lymphocytes in gut-associated lymphoid tissue, which interacts with mucosal vascular addressin cell adhesion molecule-1 (MAdCAM-1). This class of biological agents includes the integrins α4β1, α4β7 and α2β2, which interact with vascular cell adhesion molecule 1 (VCAM-1), MAdCAM-1 and intercellular adhesion molecule 1 (ICAM-1), respectively.14 These are monoclonal antibodies natalizumab (anti-α4 integrin), VDZ (anti-α4β7 integrin), AMG181 (anti-α4β7 integrin) and etrolizumab (anti-β7 integrin targeting both α4β7 and αEβ7 integrin). Others in this class are AJM-300 (inhibits the α4 integrin subunit) and alifacorsen, an antisense nucleotide against ICAM-1 messenger RNA. The interaction between α4β7 and MAdCAM-1 activates the gut-specific migration of lymphocytes to Peyer’s patches.14

VDZ is a humanized immunoglobulin (Ig) G1 monoclonal antibody, which binds to α4β7. It does not involve α4β1–VCAM interactions or T-cell trafficking to the brain or kidney. As such, it is not directly linked with risk of profligate multifocal leukoencephalopathy (PML), which is a rare viral disease associated with high mortality.15,16 VDZ received regulatory approval (The US Food and Drug Administration [FDA] and the European Medicines Agency) for the treatment of patients with moderate-to-severe UC and CD, in 2014.9-11

Recent research has indicated that VDZ may also have an effect through modulation of innate immunity, particularly macrophage populations, and this activity correlates with clinical efficacy.17

VDZ in CD

The registrational GEMINI 2 trial included patients with moderately to severely active CD and evidence of inflammation (C-reactive protein [CRP] >2.87 mg/L, faecal calprotectin >250 μg/g stool and evidence of ulcers at colonoscopy and imaging).10 It has two co-primary endpoints at week 6, namely clinical remission (Crohn’s disease activity index [CDAI] ≤150 points) and a CDAI-100 response (≥100-point decrease in CDAI; Table 1). For maintenance therapy, the primary endpoint was clinical remission at week 52. A total of 368 patients were randomized; 14.5% achieved remission on VDZ as opposed to 6.8% on placebo (p=0.02), and a CDAI-100 response was achieved by 31.3% treated with VDZ versus 25.7% on placebo (p=0.23). Clinical remission was achieved at week 52 in 39% receiving VDZ 8-weekly, 36.4% receiving VDZ 4-weekly and 21.6% receiving placebo.10

The GEMINI 3 trial had a 10-week induction period and enrolled 416 patients with moderately to severely active CD; the majority (76%) had previously failed anti-TNF therapy.11 The primary endpoint was clinical remission at week 6. Clinical remission at week 10 and a CDAI-100 response at week 6 and week 10 were secondary endpoints. There were 315 CD patients with anti-TNF intolerance or failure, of whom 15.2% treated with VDZ and 12.1% on placebo achieved clinical remission at week 6 (p=0.433). Clinical remission was achieved at week 10 by 26.6% patients treated with VDZ as against 12.1% on placebo (95% confidence interval [CI]: 1.3–3.6; p<0.001).11 VDZ was found to be more effective than placebo for induction of remission in anti-TNF-naive patients (35.3 versus 16.0%, p=0.025) in a subgroup analysis.11 A Cochrane systematic review also found that for the induction of remission, VDZ was superior to placebo (relative risk [RR]=0.86, 95% CI: 0.80–0.91).12

In a further analysis of patients enrolled in GEMINI 2 and GEMINI 3, of 516 anti-TNF-naive and 960 anti-TNF-exposed patients, clinical remission in anti-TNF-naive patients at week 6 (22.7 versus 10.6%, 95% CI: 3.7–21.4) and week 10 (26.6 versus 15.4%, 95% CI: 1.5–21.1) were noted.18 Higher rates of clinical remission were achieved by patients naïve to anti-TNF therapy at week 52, compared with placebo (48.9 versus 26.8%, 95% CI: 8.9–35.4). Among patients previously unresponsive to anti-TNF agents, clinical remission with VDZ and placebo at week 6 were comparable (13.3 versus 9.7%, 95% CI: −1.6–9.8). Clinical remission rates at week 10, however, were higher in VDZ-treated patients (21.8 versus 11.0%, 95% CI: 4.5–18.6).18

During maintenance also, clinical remission was higher for VDZ-treated patients with prior anti-TNF failure against placebo at week 52 (27.7 versus 12.8%, 95% CI: 4.7–25.0). Taken together, the data suggest that prior anti-TNF antagonist failure is associated with more refractoriness to induction therapy possibly requiring a relatively longer treatment period to demonstrate benefit. In contrast, responders to VDZ have a durable treatment benefit irrespective of prior TNF antagonist exposure.18
The GEMINI OLE study followed clinical responders from the randomized trials who completed at least 52 weeks of treatment. Sixty-one of 146 patients had 248 weeks of therapy. Of these, 95 and 89% of patients maintained clinical response and remission, respectively, with consistent treatment benefits through weeks 52 and 248.

Finally, the prevailing notion that therapies targeting lymphocyte trafficking are slow to act has been challenged by post hoc analysis of the GEMINI trials, which reported significant improvements in patient-reported outcomes of abdominal pain and stool frequency as early as 2 weeks.

‘Real-world’ experience in CD

Real-world data provide greater insights into the effectiveness of therapy in a heterogeneous and more complex patient population representative of clinical practice (Table 2). A growing body of evidence from real-world data for VDZ provides credible evidence for its effectiveness and safety. In a systematic review of data from 994 participants, clinical response and remission rates at week 6 were 54% (95% CI: 41–66%) and 22% (95% CI: 13–35%), with similar rates at week 14. Remission was noted in 32% (95% CI: 12–62%) of patients at week 52. The results were similar to the GEMINI studies although the proportion of anti-TNF-naive patients in the real-world data was very small (8.5%) as compared to GEMINI II (38.2%).

Another recent systematic review with meta-analysis of real-world data noted 30% of CD patients to be in clinical remission by week 14 (95% CI: 25–34%) and at 12 months (95% CI: 20–42%), with higher rates in bio-naive patients achieving clinical remission in 48% of patients at week 14.
### Table 2. Real-world studies for vedolizumab.

| Study                        | n             | Endpoint                          | Week 6 | Week 14 | Week 26 | Week 52 | Week 104 |
|------------------------------|---------------|-----------------------------------|--------|---------|---------|---------|----------|
| Engel et al.21†              | 1565 (994 CD, 571 UC) | CD clinical response               | 56%    | 49%     | 45%     |         |          |
|                              |               | UC clinical response               | 43%    | 51% (week 12–22) | 48%     |         |          |
|                              |               | CD clinical remission              | 22%    | 32%     | 32%     |         |          |
|                              |               | UC clinical remission              | 25%    | 30% (week 12–22) | 39%     |         |          |
| Schreiber et al.22           | 9486 (4532 CD, 3216 UC, 1738 IBDU) | CD clinical response               | 58%<sup>b</sup> | 49%<sup>b</sup> |         |         |          |
|                              |               | UC clinical response               | 56%<sup>b</sup> | 52%<sup>b</sup> |         |         |          |
|                              |               | CD clinical remission              | 24%<sup>a</sup> | 30%<sup>a</sup> | 26%<sup>a</sup> | 30%<sup>a</sup> |         |
|                              |               | UC clinical remission              | 24%<sup>a</sup> | 32%<sup>a</sup> | 39%<sup>a</sup> | 46%<sup>a</sup> |         |
|                              |               | CD CFCR                           |         |         |         |         | 31%<sup>b</sup> |
|                              |               | UC CFCR                           |         |         |         |         | 42%<sup>b</sup> |
| Kopylov et al.23             | 184 (anti-TNF naive) (50 CD, 134 UC) | CD clinical response               | 84%<sup>a</sup> |         |         |         |          |
|                              |               | UC clinical response               | 79%<sup>a</sup> |         |         |         |          |
|                              |               | CD clinical remission              | 64%<sup>b</sup> |         |         |         |          |
|                              |               | UC clinical remission              | 40%<sup>b</sup> |         |         |         |          |
|                              |               | CD mucosal healing                 |         |         |         |         |          |
|                              |               | UC mucosal healing                 |         |         |         |         |          |
|                              |               | CD CFCR                           | 52%<sup>b</sup> |         |         |         |          |
|                              |               | UC CFCR                           | 37%<sup>b</sup> |         |         |         |          |
| Lenti et al.24               | 203 (135 CD, 68 UC) | CD clinical response or remission | 79%<sup>a</sup> | 64%<sup>a</sup> |         |         |          |
| The Cross Pennine Study:     |               | UC clinical response or remission  | 91%<sup>a</sup> |         |         |         |          |
| Multicentre retrospective     |               |                                 |         |         |         |         |          |
| study                        |               |                                 |         |         |         |         |          |
| Bressler et al.25            | 419 (CD) (biologic naive) (177 VDZ, 242 anti-TNF) | Clinical response                |         |         |         |         | 74.5% VDZ versus 73.4% anti-TNF (ns) |
|                              |               | Clinical remission                |         |         |         |         | 69.7% VDZ versus 66.4% anti-TNF (ns) |
| EVOLVE: Multicentre          |               | Mucosal healing                   |         |         |         |         | 100% VDZ versus 90.1% anti-TNF (ns) |
| retrospective study          |               |                                 |         |         |         |         |          |

(Data from last follow-up (i.e. not 52 weeks))
### Table 2. (Continued)

| Study                                      | n     | Endpoint                          | Week 6  | Week 14 | Week 26 | Week 52 | Week 104 |
|--------------------------------------------|-------|-----------------------------------|---------|---------|---------|---------|----------|
| Dulai et al.26                             | 212 (CD) | Clinical remission                | 11%<sup>a</sup> | 18%<sup>a</sup> | 35%<sup>a</sup> |         |          |
| Multicentre retrospective cohort study     |       | Mucosal healing                   | 20%<sup>a</sup> |         | 63%<sup>a</sup> |         |          |
| US VICTORY Consortium:                     |       | Deep remission (clinical remission and mucosal healing) | 26%<sup>b</sup> |         |         |         |          |
| Danese et al.30                            | 101 (CD) | Clinical response                 | 60%<sup>b</sup> |         | 59%<sup>b</sup> |         |          |
| VERSIFY: Phase 3b, open-label, single-group prospective study |       | Clinical remission                | 34%<sup>b</sup> | 42%<sup>b</sup> | 50%<sup>b</sup> |         |          |
|                                            |       | Endoscopic response               | 25%<sup>b</sup> |         | 54%<sup>b</sup> |         |          |
|                                            |       | Endoscopic remission              | 12%<sup>a</sup> |         | 18%<sup>b</sup> |         |          |
|                                            |       | Complete mucosal healing           | 12%<sup>b</sup> | 15%<sup>b</sup> | 18%<sup>b</sup> |         |          |
| Lowenberg et al.31                         | 110 (CD) | Clinical response                 | 38%     |         | 35%     |         |          |
| LOVE-CD: Open-label, prospective study     |       | CFCR                              | 29%     |         | 31%     |         |          |
|                                            |       | Endoscopic response               | 40%     |         | 45%     |         |          |
|                                            |       | Endoscopic remission              | 33%     |         | 36%     |         |          |
|                                            |       | Histological remission            | 64% (GS), 66% (RHI) |         |         |         |          |
| Narula et al.33                            | 321 (UC) | Clinical response                 | 54%<sup>b</sup> |         | 75%<sup>b</sup> |         |          |
| US VICTORY Consortium:                     |       | Clinical remission                | 36%<sup>a</sup> | 51%<sup>a</sup> |         |         |          |
| Multicentre retrospective cohort study     |       | Endoscopic remission              | 18%<sup>a</sup> |         | 41%<sup>a</sup> |         |          |
|                                            |       | CFCR                              | 21%<sup>b</sup> |         | 37%<sup>b</sup> |         |          |
| Yarur et al.34                             | 527 (UC) | Clinical response                 |         |         | 90.8% VDZ versus 85.7% anti-TNF (ns) |         |          |
| (biologic naive) (325 VDZ, 202 anti-TNF)   |       | Clinical remission                |         |         | 79% VDZ versus 66.2% anti-TNF (ns) |         |          |
| EVOLVE: Multicentre retrospective study     |       | Mucosal healing                   |         |         | 92% VDZ versus 84.4% anti-TNF (ns) |         |          |

<sup>a</sup>Significant difference compared to anti-TNF group (p<0.05)

<sup>b</sup>Significant difference compared to baseline (p<0.05)
Table 2. (Continued)

| Study | n     | Endpoint       | Week 6 | Week 14 | Week 26 | Week 52 | Week 104 |
|-------|-------|----------------|--------|---------|---------|---------|----------|
| Sands et al. 37 | n=769 (UC) (383 VDZ, 386 ADA) | Treatment persistence | 75.1% VDZ versus 53.8% anti-TNF (p<0.01) |
| VARSITY: Phase 3b randomized control trial | Clinical remission | 31% VDZ versus 23% ADA (p=0.006)<sup>a</sup> |
|                | Endoscopic improvement | 40% VDZ versus 28% ADA (p<0.001)<sup>b</sup> |
|                | CFCR | 13% VDZ versus 22% ADA (ns)<sup>b</sup> |

<sup>a</sup>study primary endpoint (in bold text); <sup>b</sup>study secondary endpoint; <sup>c</sup>data from last follow-up (i.e. not 52 weeks).

ADA, adalimumab; CD, Crohn’s disease; CFCR, corticosteroid free clinical remission; GS, Geboes score; IBDU, inflammatory bowel disease unspecified; LOVE-Cd, LOw Countries VEdolizumab in CD Study; ns, not significant; RHI, Robart’s histopathology index; TNF, tumour necrosis factor; UC, ulcerative colitis; US VICTORY Consortium, US VICTORY (Vedolizumab for Health OuTComes in InflammatORY Bowel Diseases) Consortium; VDZ, vedolizumab.

(95% CI: 28–68%) and 44% of patients at 12 months (95% CI: 18–75%), respectively. 22

Kopylov and colleagues evaluated the efficacy of VDZ in 184 anti-TNF-naive patients from 23 centres across Europe.23 In patients with CD, clinical response and remission at week 14 were observed in 84 and 64% of patients, respectively. Of those who continued with maintenance treatment, 68.6% were in clinical remission at last follow-up, with 60% in corticosteroid-free clinical remission (CFCR). About 94.5% of CD patients receiving an additional week 10 dose demonstrated clinical response.23 In a multicentre UK study involving 203 patients with IBD treated with VDZ steroid, free remission at week 14 for CD was 38.3%, with 39.5% of patients (p=0.0021) in CFCR by week 52. 24

The recently presented EVOLVE study was a multicentre retrospective study, which assessed the effectiveness and safety of VDZ compared with anti-TNF agents in a real-world cohort of biologic-naive patients with CD.25 At 24 months, cumulative rates of clinical response, clinical remission, mucosal healing and dose escalation were similar in both cohorts. Treatment persistence was significantly (p<0.05) greater at 12 (86 versus 76%) and 18 (79 versus 70%) months for VDZ versus anti-TNF patients, respectively, but did not differ at 24 months (71 versus 71%). VDZ proved equally effective in a first-line biologic setting for CD over 24 months. 24

The US VICTORY (Vedolizumab for Health OuTComes in InflammatORY Bowel Diseases) Consortium included 212 patients with moderate-to-severe CD. Twelve-month cumulative rates of clinical remission, mucosal healing and deep remission (clinical remission and mucosal healing) were 35, 63, and 26%, respectively. Individuals with prior TNF antagonist exposure (hazard ratio (HR): 0.40; 95% confidence interval (CI): 0.20–0.81), smoking history (HR: 0.47; 95% CI: 0.25–0.89), active perianal disease (HR: 0.49; 95% CI: 0.27–0.88) and severe disease activity (HR: 0.54; 95% CI: 0.31–0.95) were less likely to achieve clinical remission. 26 In a subsequent publication from the same group, after adjusting for disease-related factors, including previous exposure to TNF antagonists, patients with early-stage CD (<2 years) were significantly more likely than patients with later-stage CD to achieve clinical remission (adjusted hazard ratio [aHR]: 1.59; 95% CI: 1.02–2.49), CFCR (aHR, 3.39; 95% CI: 1.66–6.92) and endoscopic remission (aHR, 1.90; 95% CI: 1.06–3.39). 26

Taken together, ‘real-world’ studies suggest that predictors of a poor response include extensive and severe disease,21,23,26–28 active perianal disease,21,26,28 smoking history,21,26,28 prior anti-TNF exposure,21,26,28 prior surgery,27 high CRP,21,27,28 lack of clinical response at week 6,29 and corticosteroid use at induction.29

The recently reported VERSIFY study was the first prospective study of endoscopic, radiologic and histologic healing in 101 patients who received VDZ therapy for moderately severe CD (CDAI 220–450), had a simple endoscopic score for CD (simple endoscopic score for Crohn’s disease [SES-CD]) of 7 or
more and experienced failure of conventional therapy. The primary endpoint was endoscopic remission (SES-CD score ≤4) at week 26, achieved by 11.9% of patients (95% CI: 6.3–9.8). By week 52, 17.9% of the patients were in endoscopic remission (95% CI: 8.9–30.4). Higher proportions of patients naive to TNF antagonists achieved endoscopic remission than patients with TNF antagonist failure at weeks 26 and 52. Higher proportion of patients with moderate CD (SES-CD scores, 7–15) achieved endoscopic remission at weeks 26 and 52 than patients with severe CD (SES-CD scores above 15). Remission was detected by magnetic resonance enterography in 21.9% of patients at week 26 (95% CI: 9.3–40.0) and in 38.1% at week 52 (95% CI: 18.1–61.8). At week 52, 20.5% of patients had a histologic response in the colon (95% CI: 9.8–35.3), and 34.3% of patients had a histologic response in the ileum (95% CI: 19.1–52.2).

The ability of VDZ to induce endoscopic and histological remission was also reported in a recent phase 4 open-label study from Europe. In addition to standard induction, patients received an additional infusion at week 10 if their CDAI score had not decreased by ≥70 points. At weeks 26 and 52, 36 patients (29%) and 34 patients (31%), respectively, were in CFCR. Endoscopic remission (SES-CD score <4) was achieved by 36 patients (33%) and 40 patients (36%) at weeks 26 and 52. Histologic remission at week 26 was observed in 43 (64%) of 67 patients based on Geboes score and 37 (66%) of 56 patients based on Robarts histopathology index scores in analyses of paired biopsies with inflammation at baseline. Serum concentrations of VDZ above 10 μg/mL at week 22 were associated with endoscopic remission at week 26.

**VDZ in UC**

In the GEMINI I study, patients with active UC were treated with VDZ (Table 1). The primary endpoint was clinical response at week 6 (defined by a reduction in the Mayo score of ≥3 points and a decrease of at least 30% from baseline, with a decrease of ≥1 point on the rectal bleeding subscore (absolute score 0–1). For maintenance therapy, the primary endpoint was clinical remission at week 52. Among 374 patients randomized to VDZ or placebo, 47.1% achieved clinical response at week 6 in the VDZ group as compared with 25.5% in the placebo group (95% CI: 11.6–31.7; p<0.001). By week 52, 41.8% of patients treated with VDZ 8-weekly, 44.8% treated with VDZ 4-weekly, and 15.9% of patients receiving placebo achieved clinical remission. A Cochrane systematic review noted that VDZ was superior to placebo for clinical response (RR=0.82, 95% CI: 0.75–0.91), induction of remission (RR=0.86, 95% CI: 0.80–0.91), endoscopic remission (RR=0.82, 95% CI: 0.75–0.91) and remission at 52 weeks in week 6 responders (RR=2.73, 95% CI: 1.78–4.18).

The GEMINI OLE included patients with at least 248 weeks of cumulative VDZ treatment (n=154). Of patients responding to induction therapy and who completed the maintenance study, 40.9% of patients had 248 weeks of treatment; 98% achieved clinical response and 90% had clinical remission. Improvements in health-related quality of life were noted.

Post hoc analysis of the GEMINI trials reported significant improvements in patient reported outcomes of reduction in rectal bleeding and stool frequency as early as 2 weeks.

**‘Real-world’ experience in UC**

A growing body of evidence from real-world data provides further credible evidence for effectiveness and safety of VDZ (Table 2). Efficacy data from 9 open-label cohorts, from 571 UC patients, noted overall week 6 response and remission rates of 43% (95% CI 37–49%) and 25% (95% CI 12–45%), respectively. The US VICTORY Consortium reported outcomes from 321 VDZ-treated UC patients, 71% of whom had failed anti-TNF treatment. Clinical and endoscopic remission was achieved at 12 months by 51 and 41% of patients, respectively. Previous anti-TNF exposure was associated with lower rates of clinical (HR: 0.53, 95% CI: 0.38–0.75) and endoscopic remission (HR: 0.51, 95% CI: 0.29–0.88).

The EVOLVE study for UC retrospectively assessed the safety and effectiveness of VDZ compared with anti-TNF agents in a real-world cohort of biologic naive patients. At 24 months, cumulative rates of clinical response (91 versus 86%), clinical remission (79 versus 66%) and mucosal healing (92 versus 84%) were high in VDZ and anti-TNF patients, respectively, and did not differ significantly between groups. Higher treatment persistence (75 versus 54%; p<0.01) occurred in VDZ versus anti-TNF patients, and dose escalation was more common in the anti-TNF group (25 versus 31%; p<0.05).

Kopylov and colleagues evaluated the efficacy of VDZ in 184 anti-TNF-naive patients from 23 centres across Europe. Among 134 UC patients, 116 (79.1%) had a clinical response to treatment by week 14, including 53 (39.5%) in clinical remission; 49/134 (36.6%) achieved CFCR. At last follow-up (42.5 weeks; interquartile range: 30–52 weeks), 79/103 (76.7%) patients had a clinical response, 69/103 (67.0%) were in clinical remission; 49/134 (36.6%) achieved CFCR. Adverse effects were reported in 20 (11%) of patients, leading to treatment discontinuation in 6 (3.3%). Taken together, real-world experience suggests that VDZ probably is more effective in anti-TNF-naive UC patients although a significant proportion of anti-TNF-exposed patients are able to attain clinical and endoscopic remission over time.

With an expanding therapeutic armamentarium, the inevitable question and challenge for clinicians and patients is choosing between treatment classes. Recently reported systematic reviews with network meta-analysis reported that VDZ and infliximab ranked highest for induction of clinical remission in biologic-naive UC patients and that VDZ was associated with the lowest risk of serious adverse events (SAEs) and infections. The VARSITY trial was the first head-to-head comparison, which compared intravenous infusions
of VDZ with subcutaneous adalimumab in a double-blind, double-dummy, randomized controlled trial. Clinical remission at week 52 occurred in a significantly higher percentage of patients who received VDZ than in those who received adalimumab (31.3 versus 22.5%), as did endoscopic improvement (39.7 versus 27.7%). The percentage of patients who had CFCR at week 52 (a key secondary endpoint) was higher in the adalimumab group than in the VDZ group (21.8 versus 12.6%). More adverse events were reported in the adalimumab group than with VDZ. Notably, previous anti-TNF exposure was allowed (albeit capped at 25%), and dose escalation was not permitted, raising questions on if and how these might have impacted the results. Nonetheless, it sets the scene for other head-to-head comparisons, which may better inform treatment choices in real-world practice.

In the light of the VARSITY trial outcomes, clinicians, who may have previously had more familiarity with prescribing anti-TNF medications as a first-line biologic in moderate-to-severe UC, can perhaps have increased confidence with choosing VDZ. In fact, the study results suggest that it may well be preferential to prescribe VDZ first line, over adalimumab, in such patients. However, while efficacy and safety data are paramount, convenience to patients, as well as cost, must also be considered. The VARSITY trial compares intravenous VDZ against subcutaneous adalimumab, and as such, the convenience to patients of the different modalities of delivery, as well as the costs involved, may factor in decisions regarding drug choice. The recently published results from the VISIBLE trial, demonstrating the efficacy and favourable safety profile of subcutaneous VDZ, will almost certainly impact upon both the cost and convenience of VDZ when considering it as a first-line biologic. Further head-to-head studies are now required to compare subcutaneous VDZ to the other available options.

Limited data exist on the cost effectiveness of VDZ as a first-line biologic treatment in patients with moderate-to-severe UC. The outcomes of the available studies are inconsistent with some favouring anti-TNF medications and others suggesting VDZ may be at least as cost-effective as other biologic treatment options. A significant limitation of these studies is that they frequently do not consider the anti-TNF biosimilars, which are now widely available, and whose use would inevitably impact upon any cost analyses.

Safety profile

Gut specificity with VDZ without systemic immunosuppression is particularly attractive. In a Groupe d’Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID) study, reporting on patients with active IBD (CD=173 and UC=121), who had an inadequate or loss of response to conventional therapy, or at least one anti-TNF agent, received standard induction and maintenance doses of VDZ. Prior treatment with corticosteroids, thiopurines or methotrexate was permitted. CFCR was achieved by 31% of patients at week 14 and clinical response in 51% patients. In patients with UC, CFCR and response rates were 36 and 50%, respectively. Severe adverse events were noted in 24 patients (8.2%); this led to VDZ discontinuation in 15 (5.1%) patients (including pulmonary tuberculosis in 1 and rectal adenocarcinoma in another patient). Integrated long-term safety data (2009–2013) from 2830 patients with 4811 patient-years (PYs) of VDZ exposure (median exposure range, 1–1977 days) showed no signals of increased risk associated with VDZ. Sepsis, tuberculosis and Clostridial infections were uncommon (≤0.6% of patients). Previous anti-TNF failure and use of narcotic analgesia use were noted to be independent risk factors for serious infection in UC, and for CD, these were corticosteroid and narcotic use and younger age. Cancer diagnoses were reported in <1% VDZ-treated (18) patients and these were colon, breast, renal, liver, lung and non-melanoma skin cancer and malignant melanoma. All (but one with renal cancer) had prior azathioprine and/or anti-TNF exposure. There was no significant increase in opportunistic infections or malignancy with anti-integrin antibodies as compared to placebo in a recent systematic review. In the GEMINI OLE study, adverse events (AEs) were reported in 137 patients, of which 17 patients discontinued treatment. Forty-four SAEs were reported, with seven considered drug-related. In a systematic review and meta-analysis of randomized controlled trials (RCTs) of 1122 UC patients, SAEs between the VDZ and placebo-treated groups were similar (12% [97/775] versus 12% [43/347]; RR: 1.02, 95% CI: 0.73–1.42).

In the GEMINI 2 study, infection risk was more frequent in VDZ-treated patients compared to placebo. SAEs were more common (24.4%) in patients treated with VDZ compared with placebo (15.3%). Four patients died in the VDZ group and one in the placebo group. One patient had breast cancer reported during VDZ induction. In the maintenance study, tuberculosis, appendiceal carcinoid tumour, squamous cell carcinoma and basal cell skin carcinoma occurred in one patient each. In GEMINI 3, AEs were comparable between VDZ (n=209) and placebo-treated (n=207) patients (56 versus 60%), respectively. No deaths were reported. In the CD GEMINI OLE study, AEs were reported in 134 patients, SAEs in 41 patients and 3 were possibly drug related. After follow-up lasting 248 weeks, only 15 patients stopped treatment following an AE.

The gut specificity of VDZ was demonstrated in a randomized trial wherein reduced seroconversion occurred following oral cholera vaccination. The response to parenteral hepatitis B vaccination was not attenuated following VDZ injection. In the GEMINI trials, intestinal infections (1 Salmonella, 3 Campylobacter and 6 Clostridium difficile) occurred after VDZ, but not placebo. As per the FDA label, patients who receive VDZ should receive live vaccines only if benefits are outweighed by potential risks. A case report of successful vaccination against measles virus while on VDZ has been
reported in a patient with Crohn’s ileocolitis. Although successful live vaccination on CD treatment is plausible, this needs further study. In keeping with expectations from its gut-specificity, PML has not been reported in trials or long-term extension studies. Finally, *C. difficile* infections in randomized trials and postmarketing studies for CD and placebo-treated patients are similar, and in fact lower than from large health population databases.

**Evolving concepts**

Although response to VDZ in IBD is promising, lack of response, as with conventional treatments, is seen in some patients. Reasons for lack of efficacy are likely multifactorial, including the heterogeneity of disease potentially rendering VDZ’s mechanism of action ineffective and failure to achieve therapeutic drug levels. This raises the importance of establishing biomarkers to predict therapeutic response as well as to obtain a better understanding of therapeutic drug levels and potential dose intensification with VDZ. These evolving concepts will now be covered.

**Therapeutic drug monitoring**

Therapeutic drug monitoring (TDM) involves measuring drug and antidrug antibody levels with adjustment of dosing on the premise that drug exposure rather than drug dose is associated with response. Although TDM-based dose adjustment is rapidly gaining momentum with anti-TNF therapies, its role with VDZ is less clear. Registrational trials for VDZ have however demonstrated an exposure–efficacy relationship. Post hoc analysis of GEMINI trials demonstrated that higher trough levels correlated with higher rates of clinical remission. Induction trough levels of <17 μg/mL for UC and <16 μg/mL for CD were associated with remission rates similar to placebo. In a subsequently published propensity score-based case-matched analysis of UC patients from the GEMINI study, adjusting for confounders affecting trough levels, target levels of 37.1 μg/mL at week 6 during induction, 18.4 μg/mL at week 14 and 12.7 μg/mL during maintenance were suggested.

Data from the largest available real-world cohorts also confirm the relationship between higher trough levels and improved outcomes. In a retrospective Belgian study, VDZ trough levels >30 μg/mL at week 2, >24 μg/mL at week 6 and >14 μg/mL during maintenance therapy, correlated with higher clinical and endoscopic effectiveness endpoints. In a cross-sectional study from the United States, patients in CFCR and biologic remission had significantly higher VDZ trough levels >30 μg/mL at week 2, >24 μg/mL at week 6 and >14 μg/mL during maintenance therapy, correlated with higher clinical and endoscopic effectiveness endpoints. Furthermore, data from France showed that VDZ trough levels below 18.5 μg/mL at week 6 were associated with the need for additional doses during the first 6 months of therapy. Higher VDZ levels have also been associated with histological remission, a rapidly evolving target.

Pooled population data from the GEMINI studies (supported by subsequent data from real-world studies) have identified low serum albumin and a high body mass index as being associated with low VDZ trough levels and worse therapeutic outcomes. Thus, low serum albumin, high CRP, and a low haemoglobin reflecting more severe disease activity are associated with a lower likelihood of achieving desired therapeutic outcomes with VDZ.

Immunogenicity appears reassuringly low with a pooled analysis of GEMINI data detecting anti-drug antibodies (ADAs) in 4% of patients. Notably, the assay used to detect ADAs in the GEMINI program was not drug tolerant. Recent real-world studies have however confirmed low immunogenicity with drug-resistant assays. This probably corroborates with the observation that the addition of an immunomodulator neither enhances drug levels nor improves therapeutic response, and the ability to use VDZ as monotherapy may be advantageous in certain patient groups.

**Treatment intensification**

Data have shown that in CD, an additional infusion at week 10 could be beneficial in patients with a suboptimal response. A low threshold for this fourth infusion should be considered to achieve induction before progressing to the 8 weekly maintenance phase. In patients with a primary response to VDZ and losing response (secondary loss of response), dose intensification from the standard 8-weekly (Q8) to 4-weekly (Q4) dosing has been shown to be able to recapture response in some patients. In clinical practice, empirical dose intensification may be required, particularly when TDM is not easily accessible and in order to make treatment decisions. This is particularly relevant as the majority of patients receiving VDZ for CD, in current clinical practice, will be ‘anti-TNF failures’, and therefore dose optimisation should be considered before a further switch in mechanistic class given further attrition with response as treatments fail patients and have to switch mechanism of action. In a recent systematic review and meta-analysis, Peyrin-Biroulet and colleagues showed that dose intensification restores responsiveness in over half of patients with UC and CD. Further real-world data from Samaan and colleagues showed recapture of response in half of their mixed IBD cohort of 36 patients receiving dose escalation.

**Candidate biomarkers predicting response to VDZ**

Recent studies have explored the possibility of individual biomarkers, which may predict whether an individual patient is more likely to respond to VDZ. Pretreatment expression of α4β7 on multiple immune cell subsets is shown to be significantly higher in responders to VDZ as is trough α4β7 receptor saturation. In another study, high pretreatment serum retinoic acid levels were predictive of achieving clinical remission with VDZ. In the same study, undetectable
levels of soluble MAdCAM-1 (s-MAdCAM-1) in maintenance therapy were strongly associated with clinical remission. Most recently, it has been shown that a number of potential biomarkers (soluble-α4β7, s-MAdCAM-1, soluble-vascular cell adhesion molecule and soluble-TNF) may help to predict the achievement of endpoints (clinical or endoscopic remission) at varying time points during treatment. Such studies have started to pave the way towards personalized therapy for patients with IBD whereby clinicians may start to predict which treatment is likely to result in the optimal outcomes for any particular patient.

**VDZ in special situations**

**Perianal CD**

In GEMINI II, at 52 weeks, 41.2% of the VDZ 8-weekly group had fistula closure as compared to 22.7% receiving VDZ 4-weekly group and 11.1% in the placebo group (p=0.03, p=0.32 versus placebo, respectively). In a postmarketing study of 35 patients who had active perianal disease, 12 patients had perianal fistula closure at 54 week follow-up. The significance of this needs further investigation. Notably, a higher incidence of perianal abscesses was reported in the GEMINI OLE study.

**Postoperative complications and recurrence risk**

Although a number of retrospective studies have suggested an increase in postoperative complications and surgical site infections with VDZ, this is not supported by meta-analysis. In the GEMINI trials, rates of surgery (VDZ: 3.6%, 51/1434; placebo: 2.4%, 7/297), post-op complications (VDZ: 5.9%, 3/51; placebo: 14.3%, 1/7), serious postoperative complications (VDZ: 2.0%, 1/51; placebo: 14.3%, 1/7) were similar to placebo. It is likely that the differences in risk estimates suggesting the increased risk in observational studies were driven by inability to control for confounders such as corticosteroid exposure and disease activity.

The effectiveness in preventing postoperative recurrence is unknown. In a retrospective study of 203 patients who underwent a CD-related surgery, 22 patients received VDZ as postoperative treatment and 58, 38 and 16 patients received anti-TNF agents, immunomodulators and metronidazole, respectively, whereas 69 patients were monitored without any medication. Rate of endoscopic remission at 6–12 months in the VDZ group was 25%, which was significantly lower compared to the anti-TNF group (66%, p=0.01). The results were supported by a propensity score-matched analysis demonstrating lower rates of endoscopic remission (25 versus 69%, p=0.03) in patients treated with VDZ as compared to anti-TNF agents. Further studies are urgently needed.

**Extraintestinal manifestations**

In post hoc analysis of the GEMINI data, patients with CD receiving VDZ in comparison to placebo had a lower risk of new or worsening arthralgia or arthritis (HR: 0.63, 95% CI: 0.44–0.89). Arthritis or arthralgia was reported to the same extent in UC, for treatment and placebo. A postmarketing study noted similar rates of extraintestinal manifestations (EIMs) in UC patients treated with VDZ and anti-TNF but more in VDZ-treated CD patients (adjusted incident rate ratio [IRR]: 1.28, 95% CI: 1.02–1.62) compared to anti-TNF patients. Notably, underlying disease activity and previous treatment were not adjusted for. In a study of 173 CD and 121 UC patients over 54 weeks, 50 patients (17.2%) had EIMs at baseline. At week 54, 45.7% (n=46) patients with arthopathy and 60% (n=5) patients with dermatological manifestations were in complete remission of EIMs. New arthropathies were seen in 15.8% (n=32) of patients, and dermatological manifestations were seen in 4.8% (n=14) patients.

**VDZ in pregnancy**

There is limited safety data for VDZ use in pregnancy, a risk category B drug. Of 24 women exposed to VDZ in pregnancy in a case series, 12 live births, 5 elective abortions and 4 spontaneous abortions were reported. Notably, with a half-life of 25 days, withholding VDZ in the third trimester may result in VDZ exposure to the foetus with prolonged drug clearance likely up to 6–12 months. The consequences of such foetal exposure are unknown. It is plausible that this may have implications for vaccination against intestinal infections such as rotavirus (which is an oral vaccine), but unlikely with parenteral agents that are administered in the first year of life. It is not possible to make evidence-based recommendations using current knowledge and any use in pregnancy should be discussed on an individual basis. Data from retrospective studies from anti-TNF-exposed paediatric patients have shown remission of 100% at 14 weeks in three patients with UC, and 44% in 9 CD patients. An ongoing phase 3 study of VDZ of patients aged 15 years and over will be reported in due course (ClinicalTrials.gov: NCT02039505).

**Conclusion**

VDZ is a much-needed addition to the increasing armamentarium of IBD therapy, and its gut specificity is particularly appealing. VDZ has shown efficacy as a first-line agent for the induction and maintenance of remission in IBD. The safety profile is promising. Real-world data have supported its effectiveness and safety profile. Recent data on mucosal healing and histological healing appear promising. Data from patient populations such as pregnancy, extremes of age, prevention of postoperative recurrence, fistulising CD and pouchitis are now urgently needed and will further refine the approach to this particularly refractory group of patients.
Contributions: BC, TB and JKL coauthored the initial draft of the manuscript. JKL subsequently revised and edited the manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: BC has a non-pharmaceutical investigator-initiated sponsored research grant from Takeda. JKL has a non-pharmaceutical investigator-initiated sponsored research grant from Takeda and has received lecture fees from Takeda. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/02/dic.2019-10-2-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2020 Crooks B, Barnes T, Limdi JK. https://doi.org/10.7573/dic.2019-10-2. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 Crooks B, Barnes T, Limdi JK. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/vedolizumab-in-the-treatment-of-inflammatory-bowel-disease:-evolving-paradigms/

Correspondence: Jimmy K Limdi, The Pennine Acute Hospitals NHS Trust, Head-Section of IBD – Division of Gastroenterology, Manchester; Manchester Academic Health Science Centre, University of Manchester; Hon Professor-Manchester Metropolitan University, Manchester, UK. Jimmy.Limdi@nhs.net

Provenance: invited; externally peer reviewed.

Submitted: 29 October 2019; Peer review comments to author: 21 January 2020; Revised manuscript received: 21 January 2020; Accepted: 27 January 2020; Publication date: 2 March 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 SPT. BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

References

1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741–1755. https://doi.org/10.1016/S0140-6736(16)31711-1
2. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. https://doi.org/10.1016/S0140-6736(16)32126-2
3. Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):351–361.e355. https://doi.org/10.1053/j.gastro.2016.09.046
4. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644–659, quiz 660. https://doi.org/10.1038/ajg.2011.73
5. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348(7):601–608. https://doi.org/10.1056/NEJMoa020888
6. Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–353. https://doi.org/10.1016/S2468-1253(19)30012-3
7. Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14(10):1385–1397.e1310. https://doi.org/10.1016/j.cgh.2016.04.039
8. Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16(1):26–42. https://doi.org/10.5217/ir.2018.16.1.26
9. Feagan BG, Rutgeertps P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. https://doi.org/10.1056/NEJMoa1215734
10. Sandborn WJ, Feagan BG, Rutgeertps P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711–721. https://doi.org/10.1056/NEJMoa1215739
11. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. *Gastroenterology*. 2014;147(3):618–627.e613. https://doi.org/10.1053/j.gastro.2014.05.008

12. Mosli MH, MacDonald JK, Bickston SJ, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. *Inflamm Bowel Dis*. 2015;21(5):1151–1159. https://doi.org/10.1097/MIB.0000000000000396

13. Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn’s disease. *Inflammopharmacology*. 2012;20(1):1–18. https://doi.org/10.1007/s10787-011-0104-6

14. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. *Gut*. 2012;61(6):918–932. https://doi.org/10.1136/gutjnl-2011-300904

15. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. *Clin Gastroenterol Hepatol*. 2008;6(12):1370–1377. https://doi.org/10.1016/j.cgh.2008.06.007

16. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. *N Engl J Med*. 2005;352(24):2499–2507. https://doi.org/10.1056/NEJMoa042982

17. Zeissig S, Rosati E, Dowds CM, et al. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. *Gut*. 2019;68(1):25–39. https://doi.org/10.1136/gutjnl-2018-316023

18. Sands BE, Sandborn WJ, Van Assche G, et al. Vedolizumab as Induction and maintenance therapy for Crohn’s disease in patients naive to or who have failed tumor necrosis factor antagonist therapy. *Inflamm Bowel Dis*. 2017;23(1):97–106. https://doi.org/10.1097/MIB.0000000000000979

19. Vermeire S, Loftus EV, Jr., Colombel JF, et al. Long-term efficacy of vedolizumab for Crohn’s disease. *J Crohns Colitis*. 2017;11(4):412–424. https://doi.org/10.1093/ecco-jcc/jjw176

20. Feagan BG, Lasch K, Lissos T, et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol*. 2019;17(1):130–138.e137. https://doi.org/10.1016/j.cgh.2018.05.026

21. Engel T, Ungar B, Yung DE, Ben-Horin S, Eliakim R, Kopylov U. Vedolizumab in IBD-lessons from real-world experience; a systematic review and pooled analysis. *J Crohns Colitis*. 2018;12(2):245–257. https://doi.org/10.1093/jecr/jcx143

22. Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. *J Gastroenterol*. 2018;53(9):1048–1064. https://doi.org/10.1007/s00535-018-1480-0

23. Kopylov U, Verstrock B, Biedermann L, et al. Effectiveness and safety of vedolizumab in anti-TNF-naive patients with inflammatory bowel disease-a multicenter retrospective European study. *Inflamm Bowel Dis*. 2018;24(11):2442–2451. https://doi.org/10.1093/ibd/izy155

24. Lenti MV, Levison S, Eliadou E, et al. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study. *Dig Liver Dis*. 2018;50(12):1299–1304. https://doi.org/10.1016/j.dld.2018.07.007

25. Bressler B, Mantzaris G, Silverberg M, et al. P621 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn’s disease patients: results from the EVOLVE study. *Journal of Crohn’s and Colitis*. 2019;13(Suppl. 1):S427–S428. https://doi.org/10.1093/ectjc/jjy222.745

26. Dulai PS, Singh S, Jiang X, et al. Vedolizumab in patients with inflammatory bowel disease: results from the US VICTORY consortium. *Am J Gastroenterol*. 2016;111(8):1147–1155. https://doi.org/10.1038/aaj.2016.236

27. Chaparro M, Garre A, Ricart E, et al. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. *Aliment Pharmacol Ther*. 2018;48(8):839–851. https://doi.org/10.1111/apt.14930

28. Barre A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. *Aliment Pharmacol Ther*. 2018;47(7):896–905. https://doi.org/10.1111/apt.14550

29. Amiot A, Grimaud JC, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2016;14(11):1593–1601. https://doi.org/10.1016/j.cgh.2016.02.016

30. Danese S, Sandborn WJ, Colombel JF, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease. *Gastroenterology*. 2019;157(4):1007–1018. https://doi.org/10.1053/j.gastro.2019.06.038

31. Lowenberg M, Vermeire S, Mostafavi N, et al. Vedolizumab induces endoscopic and histologic remission in patients with Crohn’s disease. *Gastroenterology*. 2019;157(4):997–1006. https://doi.org/10.1053/j.gastro.2019.05.067

32. Loftus EV, Jr., Colombel JF, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. *J Crohns Colitis*. 2017;11(4):400–411. https://doi.org/10.1093/ecco-jcc/jjw177

33. Narula N, Peerani F, Meserve J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. *Am J Gastroenterol*. 2018;113(9):1345. https://doi.org/10.1038/s41395-018-0162-0
34. Yarur A, Mantzaris G, Silverberg M, et al. P573 Real-world effectiveness and safety of vedolizumab and anti-TNF ulcerative colitis patients: results from the EVOLVE study. *J Crohns Colitis.* 2019;13(Suppl. 1):S400–S401. https://doi.org/10.1093/ecco-jcc/jjy222.697

35. Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. *Aliment Pharmacol Ther.* 2018;47(2):162–175. https://doi.org/10.1111/apt.14422

36. Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. *Aliment Pharmacol Ther.* 2018;47(4):454–465. https://doi.org/10.1111/apt.14449

37. Sands BE, Peyrin-Biroulet L, Loftus EV, Jr., et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. *N Engl J Med.* 2019;381(13):1215–1226. https://doi.org/10.1056/NEJMoa1905725

38. Farrell RJ. Biologics beyond anti-TNF agents for ulcerative colitis - efficacy, safety, and cost? *N Engl J Med.* 2019;381(13):1279–1281. https://doi.org/10.1056/NEJMMe1910742

39. Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. *Gastroenterology.* 2019. https://doi.org/10.1053/j.gastro.2019.08.027

40. Trigo-Vicente C, Gimeno-Ballester V, Montoiro-Allue R, Lopez-Del Val A. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain. *Expert Rev Pharmacoecon Outcomes Res.* 2018;18(3):321–329. https://doi.org/10.1080/14737167.2018.1411193

41. Yokomizo L, Limkettak P, Park KT. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. *BMJ Open Gastroenterol.* 2016;3(1):e000093. https://doi.org/10.1136/bmjgast-2016-000093

42. Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. *Eur J Health Econ.* 2018;19(2):229–240. https://doi.org/10.1007/s10198-017-0879-5

43. Wu B, Wang Z, Zhang Q. Cost-effectiveness of different strategies for the treatment of moderate-to-severe ulcerative colitis. *Inflamm Bowel Dis.* 2018;24(11):2291–2302. https://doi.org/10.1093/ibd/izy114

44. Hernandez L, Kuwabara H, Shah A, et al. Cost-effectiveness analysis of vedolizumab compared with other biologics in anti-TNF-naive patients with moderate-to-severe ulcerative colitis in Japan. *Pharmacoconomics.* 2019. https://doi.org/10.1007/s40273-019-00841-1

45. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut.* 2016. https://doi.org/10.1136/gutjnl-2015-311079

46. Luthra P, Peyrin-Biroulet L, Ford AC. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. *Aliment Pharmacol Ther.* 2015;41(12):1227–1236. https://doi.org/10.1111/apt.13215

47. Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. *Gut.* 2015;64(1):77–83. https://doi.org/10.1136/gutjnl-2014-307127

48. Wichmann A, Cleveland NK, Rubin DT. Safety and efficacy of live measles vaccine administered to a Crohn’s disease patient receiving vedolizumab. *Am J Gastroenterol.* 2016;111(4):577. https://doi.org/10.1038/ajg.2016.21

49. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut.* 2017;66(5):839–851. https://doi.org/10.1136/gutjnl-2015-311079

50. Feuerstein JD, Nguyen GC, Kuper SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. *Gastroenterology.* 2017;153(3):827–834. https://doi.org/10.1053/j.gastro.2017.07.032

51. Rosario M, French JL, Dirks NL, et al. Exposure-efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn’s disease. *J Crohns Colitis.* 2017;11(8):921–929. https://doi.org/10.1093/ecco-jcc/jjx021

52. Osterman MT, Rosario M, Lasch K, et al. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. *Aliment Pharmacol Ther.* 2019;49(4):408–418. https://doi.org/10.1111/apt.15113

53. Dreesen E, Verstockt B, Bian S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol.* 2018;16(12):1937–1946.e1938. https://doi.org/10.1016/j.cgh.2018.04.040

54. Yarur AJ, Bruss A, Naik S, et al. Vedolizumab concentrations are associated with long-term endoscopic remission in patients with inflammatory bowel diseases. *Dig Dis Sci.* 2019;64(6):1651–1659. https://doi.org/10.1007/s10620-019-05570-1

55. Ungaro RC, Yarur A, Jossen J, et al. Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease. *J Crohns Colitis.* 2019;13(8):963–969. https://doi.org/10.1093/ecco-jcc/jjz041

56. Williet N, Boschetti G, Fovet M, et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months. *Clin Gastroenterol Hepatol.* 2017;15(11):1750–1757. e1753. https://doi.org/10.1016/j.cgh.2016.11.023
57. Pouillon L, Rousseau H, Busby-Venner H, et al. Vedolizumab trough levels and histological healing during maintenance therapy in ulcerative colitis. *J Crohns Colitis*. 2019;13(8):970–975. https://doi.org/10.1093/ecco-jcc/jjz029

58. Pouillon L, Vermeire S, Bossuyt P. Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview. *BMC Med*. 2019;17(1):89. https://doi.org/10.1186/s12916-019-1323-8

59. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. *Am J Gastroenterol*. 2015;110(9):1324–1338. https://doi.org/10.1038/ajg.2015.233

60. Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. *Aliment Pharmacol Ther*. 2015;42(2):188–202. https://doi.org/10.1111/apt.13243

61. Schulze H, Esters P, Hartmann F, et al. A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. *Scand J Gastroenterol*. 2018;53(6):670–676. https://doi.org/10.1080/00365521.2018.1452974

62. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. *Gastroenterology*. 2001;120(1):13–20. https://doi.org/10.1053/gast.2001.20912

63. Van den Bergh N, Verstockt B, Tops S, Ferrante M, Vermeire S, Gils A. Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. *J Gastroenterol Hepatol*. 2019;34(7):1175–1181. https://doi.org/10.1111/jgh.14584

64. Ungar B, Kopylov U, Yavzori M, et al. Association of vedolizumab level, anti-drug antibodies, and alpha4beta7 occupancy with response in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol*. 2018;16(5):697–705.e697. https://doi.org/10.1016/j.cgh.2017.11.050

65. Peyrin-Biroulet L, Danese S, Argollo M, et al. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn's disease or ulcerative colitis: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2019;17(5):838–846.e832. https://doi.org/10.1016/j.cgh.2018.06.026

66. Samaan MA, Birdi S, Morales MS, et al. Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response. *Frontline Gastroenterology*. 2019 [epub ahead of print]. https://doi.org/10.1136/flgastro-2019-101259

67. Boden EK, Shows DM, Chiorean MV, Lord JD. Identification of candidate biomarkers associated with response to vedolizumab in inflammatory bowel disease. *Dig Dis Sci*. 2018;63(9):2419–2429. https://doi.org/10.1007/s10620-018-4924-8

68. Paul S, Williet N, Di Bernardo T, et al. Soluble mucosal addressin cell adhesion molecule 1 and retinoic acid are potential tools for therapeutic drug monitoring in patients with inflammatory bowel disease treated with vedolizumab: a proof of concept study. *J Crohns Colitis*. 2018;12(9):1089–1096. https://doi.org/10.1093/ecco-jcc/jjy077

69. Battar R, Dulai PS, Vande Casteele N, et al. Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in ulcerative colitis. *Inflamm Bowel Dis*. 2019;25(2):410–420. https://doi.org/10.1093/ibd/izy307

70. Tadibiri S, Graumad J-C, Peyrin-Biroulet L, et al. Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the Observ-IBD cohort of the Getaid. *Gastroenterology*. 2017;152(5):S396. https://doi.org/10.1016/S0016-5085(17)31562-7

71. Vermeire S, Loftus EV, Colombel JF, et al. Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of Gemini 2 completers rolling into the Gemini open-label extension study. *Gastroenterology*. 2017;152(5):S601. https://doi.org/10.1016/S0016-5085(17)32147-9

72. Lightner AL, McKenna NP, Tse CS, et al. Postoperative outcomes in vedolizumab-treated patients undergoing major abdominal operations for inflammatory bowel disease: retrospective multicenter cohort study. *Inflamm Bowel Dis*. 2018;24(4):871–876. https://doi.org/10.1093/ibd/izx076

73. Lightner AL, Mathis KL, Tse CS, et al. Postoperative outcomes in vedolizumab-treated patients undergoing major abdominal operations for inflammatory bowel disease: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2018;23(12):2197–2201. https://doi.org/10.1016/j.mib.2018.09.012

74. Lightner AL, McKenna NP, Tse CS, Raffals LE, Mathis KL. Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations. *Aliment Pharmacol Ther*. 2018;47(5):573–580. https://doi.org/10.1111/apt.14459

75. Lightner AL, Tse CS, Potter DD, Jr., Moir C. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease. *J Pediatr Surg*. 2018;53(9):1706–1709. https://doi.org/10.1016/j.jpedsurg.2017.09.019

76. Law CCY, Narula A, Lightner AL, McKenna NP, Colombel JF, Narula N. Systematic review and meta-analysis: preoperative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease. *J Crohns Colitis*. 2018;12(5):538–545. https://doi.org/10.1093/ecco-jcc/jjy022

77. Yamada A, Komaki Y, Patel N, et al. The use of vedolizumab in preventing postoperative recurrence of Crohn's disease. *Inflamm Bowel Dis*. 2018;24(3):502–509. https://doi.org/10.1093/ibd/izx054

78. Feagan BG, Sandborn WJ, Colombel JF, et al. Incidence of arthritis/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials. *J Crohns Colitis*. 2019;13(1):50–57. https://doi.org/10.1093/ecco-jcc/jjy125
79. Dubinsky MC, Cross RK, Sandborn WJ, et al. Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease. *Inflamm Bowel Dis.* 2018;24(9):1876–1882. https://doi.org/10.1093/ibd/izzy065

80. Gaidos JK, Kane SV. Overcoming challenges of treating inflammatory bowel disease in pregnancy. *Expert Rev Clin Immunol.* 2016;12(8):871–878. https://doi.org/10.1586/1744666X.2016.1166958

81. Sheridan J, Cullen G, Doherty G. Letter: vedolizumab in pregnancy. *J Crohns Colitis.* 2017;11(8):1025–1026. https://doi.org/10.1093/ecco-jcc/jjw214

82. Russell RK, Hansen R, Turner D. New treatments for ulcerative colitis: do we have pediatric data? *Expert Rev Clin Immunol.* 2016;12(7):701–704. https://doi.org/10.1080/1744666X.2016.1177459